Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.45 USD
Change Today +0.20 / 3.20%
Volume 2.4K
VSTA On Other Exchanges
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

vistagen therapeutics inc (VSTA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/19/15 - $16.50
52 Week Low
02/19/15 - $3.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

vistagen therapeutics inc (VSTA) Related Businessweek News

No Related Businessweek News Found

vistagen therapeutics inc (VSTA) Details

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes products for patients with depression, and other diseases and disorders related to the central nervous system; and cancer. The company’s principal product candidate is AV-101, an orally-active small molecule prodrug, which is in Phase II development for major depressive disorder. It is also involved in the development of CardioSafe 3D, an in vitro bioassay system for predicting potential cardiotoxicity of new chemical entities (NCEs), including drug rescue NCEs; and LiverSafe 3D, a bioassay system to predict potential liver toxicity of new drug candidates, including potential drug metabolism issues and adverse drug-drug interactions. The company has strategic collaborations with University Health Network for hPSC technology research and development; Synterys, Inc. to design, produce, and analyze drug rescue NCEs; and Cato Research, Ltd. for regulatory expertise and clinical development support. It also has cooperative research and development agreement with the U.S. National Institute of Mental Health for the Phase II clinical study of AV-101. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

8 Employees
Last Reported Date: 11/16/15
Founded in 1998

vistagen therapeutics inc (VSTA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $347.5K
Founder, President, Chief Scientific Officer ...
Total Annual Compensation: $305.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2015.

vistagen therapeutics inc (VSTA) Key Developments

VistaGen Therapeutics Announces First Patient Dosed in NIH-Sponsored Phase 2A Study of Orally Available AV-101 in Major Depressive Disorder

VistaGen Therapeutics, Inc. announced that the first patient has been dosed in a Phase 2A study of its orally available AV-101 in adult patients with treatment-resistant Major Depressive Disorder (MDD). The study is being fully funded by the U.S. National Institutes of Health (NIH), and is being conducted at the U.S. National Institutes of Mental Health (NIMH), under the direction of Principal Investigator, Carlos Zarate, Jr., M.D. Dr. Zarate is Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch (ETPB) at the NIMH, and Clinical Professor of Psychiatry and Behavioral Sciences at The George Washington University. VistaGen received clearance from the U.S. Food and Drug Administration (FDA) and the NIH to initiate the study in July 2015, after entering into a Cooperative Research and Development Agreement (CRADA) with the NIMH in February 2015. The single-site (NIH) Phase 2A study, expected to enroll between 24 and 28 adult patients with treatment resistant MDD, is a randomized, double-blind, placebo-controlled, crossover trial designed to evaluate the efficacy and safety of a single oral dose of AV-101 administered once daily for 14 days. Efficacy and safety will be evaluated using the standard Hamilton Depression Rating Scale (HDRS-17) and other widely-accepted measures of mood and depression. Top-line data is expected in the first half of 2017. AV-101 is an orally available, prodrug candidate that readily gains access to the central nervous system (CNS) after systemic administration and is rapidly converted in the brain by astrocytes into its active metabolite, 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized, potent, and highly-selective antagonist of the glycine-binding co-agonist (GlyB) site of the N-methyl-D-aspartate receptor (NMDAR). Current evidence suggests that AV-101's antagonism of NMDAR signaling may provide fast-acting antidepressant effects in the treatment of MDD. Preclinical peer-reviewed data published in the October 2015Journal of Pharmacology and Experimental Therapeutics showed rapid, dose-dependent and persistent ketamine-like antidepressant effects, without the negative side effects seen with ketamine, and other channel-blocking NMDAR antagonists. In addition, as confirmed in two Phase 1 clinical studies, using AV-101 to target the GlyB site of the NMDAR may bypass potential adverse effects that occur with ketamine, while activating similar therapeutic pathways resulting in the "glutamate surge" that has been associated with increased neurogenesis and the rapid-acting antidepressant effects of ketamine observed in previous clinical studies. While most people will experience episodic depressed mood at multiple points during their life, MDD is different.

VistaGen Therapeutics, Inc. Names Maurizio Fava to the Clinical and Scientific Advisory Board

VistaGen Therapeutics, Inc. announced that Maurizio Fava, has joined the Company's Clinical and Scientific Advisory Board, effective immediately. Dr. Fava is Director of the Division of Clinical Research of the Massachusetts General Hospital (MGH) Research Institute, Executive Vice Chair, Department of Psychiatry at MGH, and Executive Director of the MGH Clinical Trials Network and Institute (CTNI), as well as Slater Family Professor of Psychiatry at Harvard Medical School.

VistaGen Therapeutics, Inc. Proposes to Approve an Amendment to the Articles of Incorporation

VistaGen Therapeutics, Inc. proposed to approve an amendment to the Articles of Incorporation to increase the total number of the authorized shares of common stock, par value $0.001 per share (common stock), from 10.0 million shares to 30.0 million shares.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSTA:US $6.45 USD +0.20

VSTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSTA.
View Industry Companies

Industry Analysis


Industry Average

Valuation VSTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VISTAGEN THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at